高级搜索

骨肉瘤免疫治疗的现状和前景

Current Status and Prospects of Immunotherapy for Osteosarcoma

  • 摘要: 骨肉瘤(Osteosarcoma)是一种具有高度侵袭性和转移性的恶性肿瘤,预后极差,迫切需要一种可以根本改善骨肉瘤预后的新型治疗方案。肿瘤免疫治疗是通过重新激活体内的免疫系统,再次启动并维持“肿瘤-免疫循环”进而杀伤肿瘤细胞的手段。CD8+细胞毒性T淋巴细胞(CTL)、CD4+T细胞、NK细胞和NKT细胞在肿瘤免疫中发挥重要功能,而体液免疫既可发挥抗肿瘤效应,也可促进肿瘤进展。近年来在肿瘤免疫反应研究的基础上,研究者们开发了各种手段来刺激免疫系统对肿瘤的应答。本综述从增强患者自身免疫系统对肿瘤的应答和外源性增强患者免疫功能两个方面对骨肉瘤的免疫治疗进行总结。

     

    Abstract: Osteosarcoma is a malignant tumor with extreme invasiveness and metastasis as well as dismal prognosis. It is critical to rapidly find a unique therapy strategy capable of significantly improving the prognosis of osteosarcoma. Tumor immunotherapy has the potential to reawaken the immune system, restart and sustain the tumor-immune cycle in the body, resulting in the death of tumor cells. CD8+ CTL, CD4+ T cells, NK cells and NKT cells all play critical roles in tumor immunity, while humoral immunity may not only inhibit tumor growth but also enhance it. Researchers have devised various strategies to boost the immune system in recent years based on tumor immune response studies. This paper highlights and examines osteosarcoma immunotherapy from two perspectives: (1) boosting the response of patient's own immune system to the tumor; (2) exogenously improving the patient's immunological function.

     

/

返回文章
返回